Fast And Furious: How The First-To-Market Advantage Is Shrinking
Executive Summary
The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.